Send to printer »

GEN News Highlights : Jan 11, 2007

Bio-Rad Obtains License to Axis-Shield’s RA Test

Anti-CCP assay will be run on the BioPlex 2200 system.

Bio-Rad gained access to Axis-Shield's test for the early detection of rheumatoid arthritis. The assay will run on Bio-Rad's BioPlex® 2200 system and will test for anticyclic citrullinated peptide antibodies.

"The ability to incorporate an anti-CCP test as part of a rheumatoid arthritis panel will add significantly to our growing menu of autoimmune tests on the BioPlex 2200 system," points out John Goetz, Bio-Rad vp and group manager of clinical diagnostics. "As the first and only fully automated, random access multiplex testing platform, the BioPlex 2200 system is ideally suited as a platform for multimarker autoimmune testing that includes rheumatoid arthritis."